I posted this on the Noxopharm board, but it is equally relevant here.
Do I detect a modest uptick in the SP (of NOX)? I wonder whether the buyers expect the SP to increase on Thursday, when Nyrada lists?
Nyrada has developed an oral PCSK9 inhibitor, much to the chagrin of Big Pharma - who tried, and failed. It also has a drug that is expected to alleviate the effects of stroke and concussion and sound damage. My guess is that these drugs will be of great interest to other companies, but I hope that Nyrada plays hard-to-get. However it pans out, the future looks promising for Nyrada AND for Noxopharm, who will hold 40% of NYR, fully diluted.
I posted this on the Noxopharm board, but it is equally relevant...
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $23.05M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.5¢ | $90.17K | 823.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 760879 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 57758 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NYR (ASX) Chart |